Abstract
Background: Proliferative vitreoretinopathy (PVR) is partially caused by peptide growth factors, stimulating the cell by binding to a transmembrane tyrosine kinase receptor. We studied the effects of herbimycin A (HA), a tyrosine kinase inhibitor, in PVR. Methods: Toxicity studies: Electroretinography and histological studies were performed after intravitreal injection of HA. Efficacy studies: Homologous rabbit dermal fibroblasts were injected intravitreally, followed by injection of HA. The presence of tractional retinal detachment (TRD) and severity of inflammation were assessed. Results: Toxicity studies: Eyes injected with HA exhibited decrease in B-wave amplitude initially, with subsequent recovery. Histologically, damage to photoreceptors was evident after injection of high but not of low doses of HA. Efficacy studies: Inflammatory response and the development of TRD were significantly reduced with all doses of HA. Conclusions: HA (20 µM) was found to be effective and safe in preventing the development of inflammation and TRD.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 5 November 1998 Revised: 18 January 1999 Accepted: 8 March 1999
Rights and permissions
About this article
Cite this article
Imai, K., Loewenstein, A., Koroma, B. et al. Herbimycin A in the treatment of experimental proliferative vitreoretinopathy: toxicity and efficacy study. Graefe's Arch Clin Exp Ophthalmol 238, 440–447 (2000). https://doi.org/10.1007/s004170050376
Issue Date:
DOI: https://doi.org/10.1007/s004170050376